



## **BRIEWE**

risen because the crop is used for fuel production. There is no such problem with algae (though some species are used as animal fodder).

Food production and algae nurseries are not incompatible. As Professor de Baar explains, 'A big container would have to be transparent to allow sunlight to enter. It could be a vertical container of several metres high, which would be aerated with air rich in CO<sub>2</sub>. Another option is to have a mixture of algae and water flow through a series of horizontal pipes. At first the water would be quite clear, with some nutrients added, but it would end as a kind of pea soup, which could be pumped straight into a factory. The algae would be filtered out so they could be processed as fuel.'

Perhaps the water could be recycled and re-used afterwards?

#### Fred N Sanders

401 Villa Tiberina St James Road Sea Point effeness@gmail.com

- 1. Van Niekerk JP. Humans a threat to humanity. S Afr Med J 2008; 98: 163.
- Haag AL. Pond-powered biofuels: Turning algae into America's new energy. Iowa, USA: Popular Mechanics, 29 March 2007. http://www.popularmechanics.com/science/earth/4213775.html (accessed 26 May 2008).
- 3. Algaculture. http://en.wikipedia.org/wiki/Algaculture (accessed 26 May 2008)

The use of algae to assist in addressing the biofuels (and animal food) problem has merit. However, it hardly scratches the more pressing issue of the total overload of Earth as we know it by humans and our by-products. Consider that in 1973 the world emitted roughly 17 billion tons of carbon dioxide from fossil fuels, compared with 30 billion tons today. The result is a rise in atmospheric CO<sub>2</sub> from 325 parts per million (ppm) in 1973 to 385 ppm today – and increasing by 2.4 ppm each year. The production of algae to address the huge and growing problem on this scale is simply beyond human capacity. – J P van Niekerk (Managing Editor)

1. Sachs JD. Stagflation is back. Here's how to beat it. Fortune 2008; 9 June: 16-19

# Citrus aurantium – beware of the bitter orange

To the Editor: The interesting case report regarding a young man who presented with a myocardial infarction after the use of a synephrine-containing substance<sup>1</sup> raises a number of issues.

The hypothesis that the infarction might have been caused by coronary spasm followed by thrombosis may be supported by a similar case of a 28-year-old man who developed a myocardial infarct after abusing synephrine tablets.<sup>2</sup> Many patients use complementary and alternative medicines (CAMs) in conjunction with their prescribed medicines – and up to 72% of users do not inform their treating physician accordingly.<sup>3,4</sup> With the narrow therapeutic window of many commonly used medicines, the potential interactions and adverse effects when used with CAMs should not be underestimated. In this

particular context, *Citrus aurantium* (Seville or bitter orange) is found in a number of foodstuffs, including marmalade, beer (Belgian Orange Muscat) and some teas, and in overthe-counter weight-loss products. In some countries (e.g. Iran, Mexico), the dried or ripe fruit form part of local dietary traditions.

In addition to the mechanisms mentioned by the authors, in which the use of *C. aurantium* could lead to cardiovascular side-effects, is the effect on drug metabolism. C. aurantium, grapefruit (C. paradisi) and pomelo (C. maximi) contain a number of flavonoids including 6',7'-dihydroxybergamottin, which is used to selectively block the intestinal cytochrome P450 isoenzyme, CYP3A4, in bioavailability studies.<sup>5</sup> C. aurantium also contains a furocoumarin (bergapten) that inhibits CYP3A4.6 Since about a quarter of pharmaceuticals are metabolised by the CYP3A4 system (e.g. warfarin, felodipine, indinavir, simvastatin), and an inhibitory effect on this system could lead to increased serum drug levels of drugs metabolised by CYP3A4, a great potential for adverse interactions exists.<sup>5</sup> The potential negative interaction of *C. aurantium* has been noted by some drug manufacturers, where its concomitant use is contraindicated with agents such as imatinib and nilotinib, which are used in the treatment of chronic myeloid leukaemia.

A greater awareness of the potential danger of *C. aurantium* and other CAMs, when used in combination with other drugs, should contribute to increased patient safety. We therefore believe that it is reasonable to suggest that pharmaceutical manufacturers, pharmacists and prescribers take potential drug-CAM interactions into account, especially with the preparation of package inserts and when writing prescriptions. The public should be educated to be aware of the injudicious use of CAMs and that not informing their doctors of their use could have dire consequences.

## Vernon J Louw

Division of Clinical Haematology Department of Internal Medicine University of the Free State Bloemfontein louwvj.md@ufs.ac.za

### **Hymne Louw**

Department of Haematology and Cell Biology Department of Internal Medicine University of the Free State

- Smedema JP, Müller GJ. Coronary spasm and thrombosis in a bodybuilder using a nutritional supplement containing synephrine, octopamine, tyramine and caffeine. S Afr Med J 2008; 98(5): 372-373.
- Keogh AM, Baron DW. Sympathomimetic abuse and coronary artery spasm. BMJ 1985; 291: 940
- Meijerman I, Beijnen JH, Schellens JHM. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 2006; 11: 742-752.
- McCune JS, Hatfield AJ, Blackburn AA, et al. Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 2004; 12: 454-462.
- Fugh-Berman A, Myers A. Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. Exp Biol Med (Maywood) 2004; 229(8): 698-704.
- Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmaco. Ther 2001; 69: 14-23.

July 2008, Vol. 98, No. 7 **SAMJ** 



